Evidence map›Paper›PMID 35270331›Full record

ArticleInternational journal of environmental research and public health2022

Long-Term Risk of Breast Cancer after Diagnosis of Benign Breast Disease by Screening Mammography.

Marta Román, Javier Louro, Margarita Posso, Carmen Vidal, Xavier Bargalló, Ivonne Vázquez, María Jesús Quintana, Rodrigo Alcántara, Francina Saladié, Javier Del Riego and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Advancing Evidence of the Associations between specific Benign Breast Diagnoses and Future Breast Cancer Risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Marta RománEpidemiology and Evaluation Department, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.ORCID 0000-0001-9076-8918
Javier LouroEpidemiology and Evaluation Department, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.ORCID 0000-0002-2985-3301
Margarita PossoEpidemiology and Evaluation Department, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.
Carmen VidalCancer Prevention and Monitoring Program, Catalan Institute of Oncology (ICO), 08908 Barcelona, Spain.ORCID 0000-0003-2768-2710
Xavier BargallóDepartment of Radiology, Hospital Clinic, 08036 Barcelona, Spain.
Ivonne VázquezPathology Department, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.
María Jesús QuintanaDepartment of Clinical Epidemiology and Public Health, University Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.
Rodrigo AlcántaraRadiology Department, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.
Francina SaladiéEpidemiology and Cancer Prevention Service, Hospital Universitari Sant Joan de Reus, IISPV, 43204 Reus, Spain.ORCID 0000-0002-1783-4066
Javier Del RiegoDepartment of Radiology, Parc Taulí University Hospital-UAB, 08208 Sabadell, Spain.ORCID 0000-0001-9200-3505
Lupe PeñalvaBreast Cancer Screening Technical Office, Private Foundation Asil Hospital, 08402 Granollers, Spain.
Maria SalaEpidemiology and Evaluation Department, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.
Xavier CastellsEpidemiology and Evaluation Department, IMIM (Hospital del Mar Medical Research Institute), 08003 Barcelona, Spain.
On Behalf Of The Bele And Iris Study Groups
Spanish Clinical Research Network · ESHospital Del Mar · ESHospital Clínic de Barcelona · ESHospital de Sant Pau · ESInstitut Català d'Ornitologia · ESInstitut de Recerca Biomèdica Catalunya Sud · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Assessing the long-term risk of breast cancer after diagnosis of benign breast disease by mammography is of utmost importance to design personalised screening strategies. We analysed individual-level data from 778,306 women aged 50-69 years with at least one mammographic screening participation in any of ten breast cancer screening centers in Spain from 1996 to 2015, and followed-up until 2017. We used Poisson regression to compare the rates of incident breast cancer among women with and without benign breast disease. During a median follow-up of 7.6 years, 11,708 (1.5%) women had an incident of breast cancer and 17,827 (2.3%) had a benign breast disease. The risk of breast cancer was 1.77 times higher among women with benign breast disease than among those without (95% CI: 1.61 to 1.95). The relative risk increased to 1.99 among women followed for less than four years, and remained elevated for two decades, with relative risk 1.96 (95% CI: 1.32 to 2.92) for those followed from 12 to 20 years. Benign breast disease is a long-term risk factor for breast cancer. Women with benign breast disease could benefit from closer surveillance and personalized screening strategies.

Indexed as

Breast NeoplasmsFibrocystic Breast DiseaseEarly Detection of CancerFemaleHumansMammographyMass ScreeningRisk Factorsbenign breast diseasebreast neoplasmslongitudinal studiesmass screening

Identifiers

PMID35270331
PMCPMC8909630
OpenAlexW4213457997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.